# A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

> **NCT07108270** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 30 (estimated)

## Conditions studied

- Neoplasms, Endometrial

## Interventions

- **BIOLOGICAL:** Dostarlimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07108270
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108270, "A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07108270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*